⌘K

Login Start Free

Home/Filings/4/0000899243-19-028602

4//SEC Filing

Siu Christine 4

Accession 0000899243-19-028602

CIK 0001731831other

View on SEC.gov Company Profile

Filed

Dec 4, 7:00 PM ET

Accepted

Dec 5, 5:49 PM ET

Size

19.5 KB

Accession

0000899243-19-028602

Insider Transaction Report

Form 4

Period: 2019-12-03

Eidos Therapeutics, Inc.EIDX

See Remarks

Transactions

Exercise/Conversion
Common Stock
2019-12-03$0.59/sh+10,000$5,900→ 46,470 total
Sale
Common Stock
2019-12-03$57.82/sh−600$34,693→ 45,870 total
Sale
Common Stock
2019-12-03$58.95/sh−5,400$318,332→ 40,470 total
Sale
Common Stock
2019-12-03$59.65/sh−4,000$238,583→ 36,470 total
Exercise/Conversion
Common Stock
2019-12-04$0.59/sh+10,000$5,900→ 46,470 total
Sale
Common Stock
2019-12-04$58.60/sh−8,800$515,671→ 37,670 total
Sale
Common Stock
2019-12-04$59.39/sh−1,200$71,272→ 36,470 total
Exercise/Conversion
Stock Option (right to buy)
2019-12-03−10,000→ 172,191 total
Exercise: $0.59Exp: 2027-12-21→ Common Stock (10,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2019-12-04−10,000→ 162,191 total
Exercise: $0.59Exp: 2027-12-21→ Common Stock (10,000 underlying)

Footnotes (6)

[F1]Represents the weighted average sale price of the shares sold from $57.275 to $58.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 through 5.
[F2]Represents the weighted average sale price of the shares sold from $58.37 to $59.225 per share.
[F3]Represents the weighted average sale price of the shares sold from $59.37 to $60.35 per share.
[F4]Represents the weighted average sale price of the shares sold from $58.11 to $59.10 per share.
[F5]Represents the weighted average sale price of the shares sold from $59.125 to $59.58 per share.
[F6]The shares subject to this option vest and become exercisable in 48 equal monthly installments after December 1, 2017, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Eidos Therapeutics, Inc.

CIK 0001731831

Entity typeother

Related Parties

1

filerCIK 0001743029

Filing Metadata

Form type: 4
Filed: Dec 4, 7:00 PM ET
Accepted: Dec 5, 5:49 PM ET
Size: 19.5 KB

View on SEC.gov